Ovarian Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Ovarian Cancer, including details on symptoms, causes, treatment, information.

Volume 3 (2006), Issue 8 (August)

1. Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary.
   Obstet Gynecol, 108(2): 361-8. [Abstract] [Full-text]
2. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO.
   J Natl Cancer Inst, 98(15): 1036-45. [Abstract] [Full-text]
3. Phase I study of pegylated liposomal doxorubicin in combination with ifosfamide in pretreated ovarian cancer patients.
   Am J Clin Oncol, 29(4): 399-404. [Abstract] [Full-text]
4. Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells.
   Cancer Immunol Immunother, 55(11): 1384-95. [Abstract] [Full-text]
5. Paclitaxel (Taxol) upregulates expression of functional interleukin-6 in human ovarian cancer cells through multiple signaling pathways.
   Oncogene, 25(35): 4857-66. [Abstract] [Full-text]
6. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells.
   Endocrinology, 147(9): 4179-91. [Abstract] [Full-text]
7. Galectin-1: biphasic growth regulation of Leydig tumor cells.
   Glycobiology, 16(9): 810-21. [Abstract] [Full-text]
8. Frequent gene dosage alterations in stromal cells of epithelial ovarian carcinomas.
   Int J Cancer, 119(6): 1345-53. [Abstract] [Full-text]
9. Silencing of the UCHL1 gene in human colorectal and ovarian cancers.
   Int J Cancer, 119(6): 1338-44. [Abstract] [Full-text]
10. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer.
    Int J Cancer, 119(6): 1412-8. [Abstract] [Full-text]
11. Percutaneous radiofrequency ablation of ovarian cancer metastasis to the liver: indications, outcomes, and role in patient management.
    AJR Am J Roentgenol, 187(3): 746-50. [Abstract] [Full-text]
12. Contrast-enhanced CT for differentiation of ovarian metastasis from gastrointestinal tract cancer: stomach cancer versus colon cancer.
    AJR Am J Roentgenol, 187(3): 741-5. [Abstract] [Full-text]
13. Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid.
    Oncogene, 25(38): 5315-25. [Abstract] [Full-text]
14. Chromosomal losses of regions on 5q and lack of high-level amplifications at 8q24 are associated with favorable prognosis for ovarian serous carcinoma.
    Genes Chromosomes Cancer, 45(10): 905-17. [Abstract] [Full-text]
15. Regulation of angiogenesis and tumor growth by p110 alpha and AKT1 via VEGF expression.
    J Cell Physiol, 209(1): 56-66. [Abstract] [Full-text]
16. Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.
    Br J Cancer, 95(5): 627-33. [Abstract] [Full-text]
17. Risk of breast, ovary, and uterine corpus cancers among 85,268 women with AIDS.
    Br J Cancer, 95(5): 642-8. [Abstract] [Full-text]
18. M-CAM expression as marker of poor prognosis in epithelial ovarian cancer.
    Int J Cancer, 119(8): 1920-6. [Abstract] [Full-text]
19. Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to beta-catenin expression.
    Int J Cancer, 119(8): 1792-9. [Abstract] [Full-text]
20. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer.
    J Surg Oncol, 94(4): 316-24. [Abstract] [Full-text]
21. Histone modifications silence the GATA transcription factor genes in ovarian cancer.
    Oncogene, 25(39): 5446-61. [Abstract] [Full-text]

© 2004-2008 Ovarian Cancer Research Today. All Rights Reserved.